← Trials/Trial dossier/NCT02501850

EGLIPA

UnknownPhase 4

The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

Lead sponsor

Hospital Universitari Vall d'Hebron Research Institute

Assets

Exenatide / Liraglutide / Lixisenatide

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Blood levels of Lipoprotein (a) (Lp(a))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02501850

Org study IDVHI-GLP-2014-01

Timeline

Milestones

Study first posted2015-07-17estimated

Last update posted2015-07-21estimated

Study start2014-10 (month precision)

Primary completion2015-07estimated (month precision)

Study completion2015-10estimated (month precision)

Assets

Investigational agents

Exenatide Liraglutide Lixisenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age50 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes

•age between 50-65 years

•written informed consent

Exclusion criteria

•active GLP-1R agonist, insulin or DPP-IV treatment.

•Liver failure (3lsn AST and/or ALT)

•Kidney failure (FG <30ml/min/1,73m2),

•HbA1c> 10%

•LDL-cholesterol> 180 mg/dl

•Triglycerides> 350 mg/dl

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiometabolic biomarkers

1 endpoint

Primary/protocol endpoint

Change in blood levels of Lipoprotein (a) (Lp(a))

Time frame:Baseline and two months

change from baseline, improvement

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies.
Clinical laboratory2011 (year)PMID21500721via CT.gov background
Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study.
Diabetes care2005 Apr (month)PMID15793200doi:10.2337/diacare.28.4.931via CT.gov background
Biological variation of lipoprotein(a) in a diabetic population. Analysis of the causes and clinical implications.
Clinical chemistry and laboratory medicine2003 Aug (month)PMID12964817doi:10.1515/CCLM.2003.166via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.